GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (STU:6L8) » Definitions » Debt-to-Equity

Pulse Biosciences (STU:6L8) Debt-to-Equity : 0.08 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Pulse Biosciences Debt-to-Equity?

Pulse Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €1.29 Mil. Pulse Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €7.20 Mil. Pulse Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €109.69 Mil. Pulse Biosciences's debt to equity for the quarter that ended in Dec. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pulse Biosciences's Debt-to-Equity or its related term are showing as below:

STU:6L8' s Debt-to-Equity Range Over the Past 10 Years
Min: -33.79   Med: 0.21   Max: 0.5
Current: 0.08

During the past 11 years, the highest Debt-to-Equity Ratio of Pulse Biosciences was 0.50. The lowest was -33.79. And the median was 0.21.

STU:6L8's Debt-to-Equity is ranked better than
73.58% of 689 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs STU:6L8: 0.08

Pulse Biosciences Debt-to-Equity Historical Data

The historical data trend for Pulse Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Debt-to-Equity Chart

Pulse Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.32 -33.79 0.21 0.08

Pulse Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.25 0.32 0.11 0.08

Competitive Comparison of Pulse Biosciences's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Debt-to-Equity falls into.


;
;

Pulse Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pulse Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Pulse Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulse Biosciences  (STU:6L8) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Pulse Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Pulse Biosciences Headlines

No Headlines